Literature DB >> 24191286

Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone.

Jenifer M Brown1, Jonathan S Williams, James M Luther, Rajesh Garg, Amanda E Garza, Luminita H Pojoga, Daniel T Ruan, Gordon H Williams, Gail K Adler, Anand Vaidya.   

Abstract

Observational studies in primary hyperaldosteronism suggest a positive relationship between aldosterone and parathyroid hormone (PTH); however, interventions to better characterize the physiological relationship between the renin-angiotensin-aldosterone system (RAAS) and PTH are needed. We evaluated the effect of individual RAAS components on PTH using 4 interventions in humans without primary hyperaldosteronism. PTH was measured before and after study (1) low-dose angiotensin II (Ang II) infusion (1 ng/kg per minute) and captopril administration (25 mg×1); study (2) high-dose Ang II infusion (3 ng/kg per minute); study (3) blinded crossover randomization to aldosterone infusion (0.7 µg/kg per hour) and vehicle; and study (4) blinded randomization to spironolactone (50 mg/daily) or placebo for 6 weeks. Infusion of Ang II at 1 ng/kg per minute acutely increased aldosterone (+148%) and PTH (+10.3%), whereas Ang II at 3 ng/kg per minute induced larger incremental changes in aldosterone (+241%) and PTH (+36%; P<0.01). Captopril acutely decreased aldosterone (-12%) and PTH (-9.7%; P<0.01). In contrast, aldosterone infusion robustly raised serum aldosterone (+892%) without modifying PTH. However, spironolactone therapy during 6 weeks modestly lowered PTH when compared with placebo (P<0.05). In vitro studies revealed the presence of Ang II type I and mineralocorticoid receptor mRNA and protein expression in normal and adenomatous human parathyroid tissues. We observed novel pleiotropic relationships between RAAS components and the regulation of PTH in individuals without primary hyperaldosteronism: the acute modulation of PTH by the RAAS seems to be mediated by Ang II, whereas the long-term influence of the RAAS on PTH may involve aldosterone. Future studies to evaluate the impact of RAAS inhibitors in treating PTH-mediated disorders are warranted.

Entities:  

Keywords:  aldosterone; calcium; parathyroid hormone; renin-angiotensin system; spironolactone; vitamin D

Mesh:

Substances:

Year:  2013        PMID: 24191286      PMCID: PMC3898197          DOI: 10.1161/HYPERTENSIONAHA.113.01910

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  49 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Vitamin D3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: an interventional study.

Authors:  Anand Vaidya; Bei Sun; Carol Larson; John P Forman; Jonathan S Williams
Journal:  J Clin Endocrinol Metab       Date:  2012-04-26       Impact factor: 5.958

Review 3.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

4.  Influence of renin-angiotensin system on serum parathyroid hormone levels in uremic patients.

Authors:  Fumihiko Koiwa; Daisuke Komukai; Makoto Hirose; Ashio Yoshimura; Ryoichi Ando; Toshifumi Sakaguchi; Yasuhiro Komatsu; Toshio Shinoda; Daijo Inaguma; Nobuhiko Joki; Hidemi Nishida; Masato Ikeda; Takashi Shigematsu
Journal:  Clin Exp Nephrol       Date:  2011-09-14       Impact factor: 2.801

5.  Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.

Authors:  Andreas Tomaschitz; Stefan Pilz; Eberhard Ritz; Andreas Meinitzer; Bernhard O Boehm; Winfried März
Journal:  Eur Heart J       Date:  2010-03-02       Impact factor: 29.983

6.  How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?

Authors:  R J MacFadyen; A F Lee; J J Morton; S D Pringle; A D Struthers
Journal:  Heart       Date:  1999-07       Impact factor: 5.994

7.  25-Hydroxyvitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians.

Authors:  Anand Vaidya; John P Forman; Paul N Hopkins; Ellen W Seely; Jonathan S Williams
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2011-02-17       Impact factor: 1.636

8.  Circulating aldosterone and mortality in female nursing home residents.

Authors:  Andreas Tomaschitz; Stefan Pilz; Burkert Pieske; Eberhard Ritz; Winfried März; Andreas Meinitzer; Harald Dobnig; Karin Amrein; Katharina Kienreich; Nicolas Verheyen; Elisabeth Kraigher-Krainer; Christiane Drechsler; Caterina Colantonio; Doris Wagner; Astrid Fahrleitner-Pammer
Journal:  Exp Gerontol       Date:  2013-01-16       Impact factor: 4.032

9.  Bone involvement in aldosteronism.

Authors:  Antonio Stefano Salcuni; Serena Palmieri; Vincenzo Carnevale; Valentina Morelli; Claudia Battista; Vito Guarnieri; Giuseppe Guglielmi; Gaetano Desina; Cristina Eller-Vainicher; Paolo Beck-Peccoz; Alfredo Scillitani; Iacopo Chiodini
Journal:  J Bone Miner Res       Date:  2012-10       Impact factor: 6.741

10.  Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial.

Authors:  Andreas Tomaschitz; Astrid Fahrleitner-Pammer; Burkert Pieske; Nicolas Verheyen; Karin Amrein; Eberhard Ritz; Katharina Kienreich; Jörg H Horina; Albrecht Schmidt; Elisabeth Kraigher-Krainer; Caterina Colantonio; Andreas Meinitzer; Stefan Pilz
Journal:  BMC Endocr Disord       Date:  2012-09-13       Impact factor: 2.763

View more
  25 in total

1.  Disentangling the Relationships Between the Renin-Angiotensin-Aldosterone System, Calcium Physiology, and Risk for Kidney Stones.

Authors:  Omar Bayomy; Sarah Zaheer; Jonathan S Williams; Gary Curhan; Anand Vaidya
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

Review 2.  The renin-angiotensin-aldosterone system and calcium-regulatory hormones.

Authors:  A Vaidya; J M Brown; J S Williams
Journal:  J Hum Hypertens       Date:  2015-01-29       Impact factor: 3.012

3.  Double hit! A unique case of resistant hypertension.

Authors:  Kristen Elizabeth DeCarlo; Nidhi Agrawal
Journal:  BMJ Case Rep       Date:  2017-12-22

4.  Blood pressure variability is independent of systolic pressure in adolescent and young adult patients undergoing hemodialysis.

Authors:  Jingjing Da; Zulong Zhang; Yan Shen; Qian Li; Ying Hu; Yan Zha
Journal:  Pediatr Res       Date:  2018-01-03       Impact factor: 3.756

Review 5.  Potential Role of Antihypertensive Medications in Preventing Excessive Arterial Stiffening.

Authors:  Guanghong Jia; Annayya R Aroor; Luis A Martinez-Lemus; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2018-07-06       Impact factor: 5.369

6.  Hypertension, Antihypertensive Medications, and Risk of Incident Primary Hyperparathyroidism.

Authors:  Anand Vaidya; Gary C Curhan; Julie M Paik; Henry Kronenberg; Eric N Taylor
Journal:  J Clin Endocrinol Metab       Date:  2015-04-17       Impact factor: 5.958

7.  Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis.

Authors:  Jenifer Brown; Ian H de Boer; Cassianne Robinson-Cohen; David S Siscovick; Bryan Kestenbaum; Matthew Allison; Anand Vaidya
Journal:  J Clin Endocrinol Metab       Date:  2014-11-20       Impact factor: 5.958

8.  Dysregulated aldosterone secretion in persons of African descent with endothelin-1 gene variants.

Authors:  Jia W Tan; Tina Gupta; Worapaka Manosroi; Tham M Yao; Paul N Hopkins; Jonathan S Williams; Gail K Adler; Jose R Romero; Gordon H Williams
Journal:  JCI Insight       Date:  2017-12-07

9.  Molecular pathways associated with transcriptional alterations in hyperparathyroidism.

Authors:  Fang Lee; Jie-Jen Lee; Woan-Ching Jan; Chih-Jen Wu; Han-Hsiang Chen; Shih-Ping Cheng
Journal:  Oncol Lett       Date:  2016-05-25       Impact factor: 2.967

10.  The effect of vitamin D3 supplementation on markers of cardiovascular health in hyperparathyroid, vitamin D insufficient women: a randomized placebo-controlled trial.

Authors:  Lise Sofie Bislev; Lene Langagergaard Rødbro; Jesper Nørgaard Bech; Erling Bjerregaard Pedersen; Alisa D Kjaergaard; Søren Andreas Ladefoged; Lars Rolighed; Tanja Sikjaer; Lars Rejnmark
Journal:  Endocrine       Date:  2018-07-24       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.